



FY 2014 Results Presentation

24 February, 2015

Senior management presenting



Prasanth Manghat
Deputy CEO



Roy Cherry
Head of Strategy & IR



Suresh Krishnamoorthy
CFO

Contents

1. **FY 2014 highlights**
2. Financial performance & analysis
3. Strategy update
4. New Financing facility
5. Acquisition
6. Outlook
7. Appendix

FY 2014 highlights

- In FY 2014 NMC Health achieved good growth across the business, supported by strong growth in the UAE economy, clear vision and dedicated management efforts to execute the strategy
- We delivered double digit growth in revenues, EBITDA and net profits
- We completed and started operations at three new healthcare facilities, two hospitals and a medical centre. One in each of Abu Dhabi, Dubai and Al Ain
- Brightpoint Royal Women's Hospital, the first private sector women's hospital in Abu Dhabi opened in July 2014. We also opened the NMC General Hospital in Dubai Investment Park at the same time. In December 2014 we started receiving patients at the NMC Medical Centre in Al Ain.
- NMC Super Specialty Hospital in the Khalifa City suburb to Abu Dhabi continued to make progress and we continue to expect opening at the end of H1 2015.
- Distribution Division continued to perform well during the year. Substantial additions to our product line-up in the distribution business were made, some of which had direct and material market impact
- With our organic expansion nearing completion, we have begun preparation for the next phase of NMC's growth by updating our strategy. On 16 February 2015 we announced a new \$825m financing facility had been secured by NMC which will serve to improve our funding efficiency and strategic capabilities.
- Today we announced the acquisition of Clinica Eugin, a leading global IVF Centre

Contents



1. FY 2014 highlights
2. **Financial performance & analysis**
3. Strategy update
4. New Financing facility
5. Acquisition
6. Outlook
7. Appendix

Group EBITDA reached US\$ 102.5m in FY 2014

Consolidated overview

- FY 2014 revenue reached US\$ 643.9m, a 16.9% YoY growth
- EBITDA increased by 10.2% to US\$ 102.5m
- EBITDA margin reached 15.9%, a decline of 96bps YoY
- EBITDA excluding the initial negative income impact by new assets, would be US\$ 108.3m and 15.6% higher YoY. Implied EBITDA margin would be 17.1%, 18bps higher YoY
- Net profit was US\$ 77.5m, a 12.1% YoY growth. Excluding impact from new assets, net profit would be US\$83.4m with a YoY growth of 20.6%
- Net profit margin declined by 51bps YoY to 12.0%. Adjusted net profit increased by 58bps to 13.1%

Performance




Operating cash flows stable, considering new asset openings

Consolidated overview


- Adjusted operating cash flow for the Group amounted to US\$ 81.8m in FY 2014. This is in-line with 2013, when considering the impact of new facilities
- More effective management of working capital reduced the net working capital to sales ratio by 142bps YoY to 32.4% in FY 2014
- Net debt was at US\$ 113.0m, compared to US\$ 63.7m in FY 2013
- Book value increased by 16.3% to US\$ 449m in FY 2014

Performance

Adjusted operating cash flow US\$m



Net working capital as % of sales



Summary financial statements

Income statement			
Details	2012	2013	2014
Audited, USD '000			
Healthcare	251,649	289,294	332,197
Distribution	271,074	300,176	338,893
Elimination	(32,669)	(38,592)	(27,159)
Revenue	490,054	550,878	643,931
<i>Growth</i>	10.4%	12.4%	16.9%
<i>Change</i>		198bps	448bps
Direct costs	(329,800)	(365,336)	(434,725)
Gross profit	160,254	185,542	209,206
<i>GPM</i>	32.7%	33.7%	32.5%
<i>Change</i>	175bps	98bps	-119bps
G&A, Net Off Other Incomes	(80,635)	(92,602)	(106,748)
<i>% of rev</i>	16.5%	16.8%	16.6%
<i>Change</i>	138bps	36bps	-23bps
EBITDA			
Healthcare	68,189	81,668	88,211
Distribution	26,208	29,907	34,121
HQ	(14,778)	(18,635)	(19,873)
Adjusted EBITDA	79,619	92,940	102,458
<i>Growth</i>	13.0%	16.7%	10.2%
<i>Change</i>		372bps	-649bps
EBITDA margin			
Healthcare	27.1%	28.2%	26.6%
<i>Change</i>	138bps	113bps	-168bps
Distribution	9.7%	10.0%	10.1%
<i>Change</i>	-9bps	29bps	11bps
<i>Consolidated EBITDA margin</i>	16.2%	16.9%	15.9%
<i>Change</i>	37bps	62bps	-96bps
Finance charges	(13,738)	(14,344)	(14,050)
Finance income	4,324	3,814	3,623
Depreciation	(7,038)	(9,663)	(14,497)
Unamortised finance fees (write-off)	-	(3,394)	-
Others	(3,402)	(210)	-
Floation costs	-	-	-
Tax	-	-	-
Net profit	59,766	69,143	77,534
<i>Growth</i>	36.5%	15.7%	12.1%
<i>NPM</i>	12.2%	12.6%	12.0%
<i>Change</i>	233bps	36bps	-51bps
Minority interest	(875)	(978)	(968)
Attributable to shareholders	58,891	68,165	76,566

Balance sheet			
Details	2012	2013	2014
Audited, USD '000			
Assets			
Property & Equipment	201,653	273,791	368,357
Investments in subsidiaries	-	-	-
Intangible Assets (Goodwill)	1,016	1,016	4,236
Non Current Assets	202,669	274,808	372,593
Inventories	72,458	94,123	110,209
Receivables & prepayments	181,402	168,382	196,569
Due from other related parties	1,602	9,254	7,985
Bank deposits	233,703	193,366	183,577
Bank balances & cash	23,747	75,329	79,592
Current Assets	512,911	540,455	577,932
Total assets	715,580	815,262	950,525
Share capital	29,566	29,566	29,566
Reserve	-	-	-
Share Premium	179,152	179,152	179,152
Group Restructuring Reserve	(10,001)	(10,001)	(10,001)
Shareholders' account	-	-	-
Retained Earning	130,952	187,519	250,239
Other Capital Reserve			67
Shareholders equity	329,669	386,236	449,023
Minority interest	1,934	2,915	4,004
Total equity	331,603	389,151	453,027
Term loans	118,428	161,845	114,457
EOSB	8,634	10,036	12,450
Other payables	1,225	408	21
Non-current liabilities	128,287	172,289	126,928
Accts. payables & accruals	68,613	76,087	98,044
Due to related parties	123	5,079	8,380
Short term borrowings	80,668	82,238	169,607
Term loans	104,540	88,355	92,055
EOSB	1,746	2,063	2,484
Current Liabilities	255,690	253,822	370,570
Total Liabilities	383,977	426,111	497,498
Total Equity & Liabilities	715,580	815,262	950,525

Summary financial statements (continued)

Cash flow			
Details	2012	2013	2014
Audited, USD '000			
Net cash from operating activities	35,267	85,071	85,682
Net cash (used in) investing activities	(258,047)	(108,087)	(27,053)
Net cash (used in) from financing activities	280,285	20,287	(1,511)
Increase / (decrease) in cash and cash equivalents	57,505	(2,729)	57,118
Cash and cash equivalents (Opening)	24,425	81,930	79,201
Cash and cash equivalents (Closing)	81,930	79,201	136,319

Definitions

Adjusted EBITDA: Non-IFRS item, adjusted for exceptional items like pre-operative expenses

Adjusted operating cash flow: Adjusted EBITDA less: changes in working capital, cash payments for PPE

Contents

Financial performance & Analysis



Healthcare Division FY 2014

Healthcare revenues increased by 14.8% in FY 2014

Performance



- Healthcare Division revenues increased by 14.8% YoY to reach a total of US\$ 332.2m in FY 2014
- Division reported EBITDA was US\$ 88.2m, 12.5% higher YoY
- Excluding impact from new asset openings, the EBITDA margin increased by 85bps to 29.1% on EBITDA of US\$ 94.1m
- Healthcare accounted for 49.5% of group revenues before eliminations and contributed 72% of EBITDA

Key figures



Healthcare revenues increased by 14.8% in FY 2014 (Continued)

Key performance indicators



NMC healthcare assets as of FY 2014 end

- Abu Dhabi Specialty Hospital contributed US\$ 111.1m in FY 2014 revenues (+10.1% YoY). Occupancy increased to 81%
- Dubai Specialty Hospital's revenues reached US\$ 65.6m in FY 2014 (+17.3% YoY) and occupancy increased to 66%
- Al Ain Specialty Hospital's revenues amounted to US\$ 58.0m in FY 2014 (+20.5% YoY) and occupancy rose to 69% (+1020bps YoY)
- Brightpoint and DIP assets soft opening in H2 2014 with initial outpatient operations. Ramp-up in FY 2015, marketing campaign initiated and inpatient services to start soon
- We increased the number of doctors to 603 in FY 2014 (+19.9% YoY)

Detail	NMC Abu Dhabi	NMC Al Ain	Brightpoint	NMC Sp. Dubai	NMC Dubai	DIP	BR Med.	MBZC	AAMC	NMC Sharjah	Total
Established	1975	2008	2014	2004	1999	2014	2011	2013	2014	1996	N/A
Emirate	Abu Dhabi	Abu Dhabi	Abu Dhabi	Dubai	Dubai	Dubai	Dubai	Abu Dhabi	Abu Dhabi	Sharjah	N/A
City	Abu Dhabi	Al Ain	Abu Dhabi	Dubai	Dubai	Dubai	Dubai	Abu Dhabi	Al Ain	Sharjah	N/A
Location	City centre	City Centre	Muroor	Al Nahda	Deira	DIP	DHCC	MBZC	Saniya	City Centre	N/A
Owned/Leased	Leased	Leased	Leased	Owned	Leased	Leased	Leased	Leased	Leased	Leased	N/A
Category	S. Hospital	S. Hospital	S. Hospital	S. Hospital	G. Hospital	G. Hospital	D. Surgery	D. Surgery	D. Surgery	M. Centre	N/A
Accreditation	JCI	JCI	JCI Plan	JCI	-	JCI Plan	-	-	-	-	-
Revenue (USD '000)	111,062	57,980	929	65,599	13,902	2,496	3,608	5,342	3	12,785	273,706
Growth, YoY	10.1%	20.5%	N/A	17.3%	13.7%	N/A	40.0%	489.7%	N/A	24.2%	18.5%
Revenue/patient	109	121	122	175	65	96	262	65	99	74.9	115
Growth, YoY	1.3%	3.2%	N/A	6.5%	4.7%	N/A	-2.5%	36.3%	N/A	11.0%	2.6%
Capacity											
Licensed beds	100	100	100	100	10	60	N/A	N/A	N/A	N/A	470
Operational beds	100	83	N/A	94	10	N/A	N/A	N/A	N/A	N/A	287
Growth, YoY	0%	38%	N/A	3%	0%	N/A	N/A	N/A	N/A	N/A	10.0%
Spare capacity (beds %)	0%	17%	N/A	6%	0%	N/A	N/A	N/A	N/A	N/A	38.9%
Staff	1,448	808	83	727	269	322	47	191	60	174	3,895
Patients											
Inpatients	21,620	10,380	N/A	10,096	1,348	N/A	N/A	N/A	N/A	N/A	43,444
Outpatients	996,653	470,685	7,636	365,492	213,384	26,044	13,760	82,372	27	170,727	2,346,780
Total	1,018,273	481,065	7,636	375,588	214,732	26,044	13,760	82,372	27	170,727	2,390,224
Growth, YoY	8.7%	16.8%	N/A	10.1%	8.6%	N/A	43.6%	332.6%	N/A	12.0%	15.6%
Bed Occupancy	81%	69%	N/A	66%	45%	N/A	N/A	N/A	N/A	N/A	71.3%
Change, YoY	170bps	876bps	N/A	1166bps	129bps	N/A	N/A	N/A	N/A	N/A	660bps

Healthcare expansion program

- Our expansion program at the time of the IPO in 2012 included three hospitals (410 licensed beds) and two day surgeries. In 2013 we also announced plans to open a medical center in Al Ain. A total of six healthcare assets
- As of FY 2014 end NMC has opened 5 out of the planned 6 assets, 3 of which commenced operations in H2 2014
- Starting in July 2014 (H2 2014) we opened and commenced initial operations in Brightpoint Women's Hospital (Abu Dhabi, 100 licensed beds) and DIP General Hospital (Dubai, 60 licensed beds)
- Al Ain Medical Center opened in Q4 2014
- Khalifa City Specialty Hospital (Abu Dhabi, 250 licensed beds) is progressing well with the external structure including façade almost complete. Work has commenced internally. We expect to open in H1 2015

NMC Health's projects

Detail	Brightpoint	DIP	Al Ain	Khalifa City	Total
Opening (expected)	Opened July 2014	Opened July 2014	Opened Dec 2014	H1 2015	N/A
Emirate	Abu Dhabi	Dubai	Abu Dhabi	Abu Dhabi	N/A
City	Abu Dhabi	Dubai	Al Ain	Abu Dhabi	N/A
Location	City Centre	Dubai Invest. Park	Industrial Area	AD Suburb	N/A
Owned/Leased	Leased	Leased	Leased	Owned	
Category	Womens Hospital	General Hospital	Medical Centre	Specialty Hospital	N/A
Capex (US\$m)	70	30	7	200	307
New assets	1	1	1	1	4
Capacity					
Licensed beds	100	60	-	250	410
Starting inpatient services	60 beds in H1 2015	30 beds in H1 2015	-	75	165
Beds phased over future periods	40	30	-	175	245

Contents

Financial performance & Analysis



Distribution Division FY 2014

Distribution records 12.9% YoY top-line growth

Distribution



- Distribution revenue increased by 12.9% YoY in FY 2014, to reach US\$ 338.9m
- Division EBITDA recorded a 14.1% growth YoY and amounted to US\$ 34.1m
- EBITDA margin increased by 11bps in FY 2014 to reach 10.1%
- Our performance improvement is mainly driven by:
 - Sustained strong growth in the UAE economy
 - Addition of new brands, some with already established demand allowing for faster roll-out
- Distribution accounted for 50% of the Group's top-line and 28% of EBITDA

Performance



Distribution records 12.9% YoY top-line growth (continued)

Key performance indicators



Contents

1. FY 2014 highlights
2. Financial performance & analysis
3. **Strategy update**
4. New Financing facility
5. Acquisition
6. Outlook
7. Appendix

NMC is embarking upon on the next phase of its Group Strategy

- 1 ■ Accelerating the establishment of Centres of Excellence in key specialties within its hospitals



- 2 ■ Increasing its participation in the rapidly growing medical tourism industry within the UAE by establishing its facilities as a destination of choice for medical tourists



- 3 ■ Growing its medical specialty offering and clinic network within the UAE and maximising operational synergies in the region

Ongoing Assessment

- 4 ■ Selectively establishing a strategic presence outside the UAE via acquisitions of, or collaborations with, leading global medical institutions



- 5 ■ Increasing its footprint in Saudi Arabia and the broader GCC region via organic initiatives and acquisitions

Ongoing Assessment

Supporting the Group Strategy

- 1 ■ Strengthening senior and mid-level management capabilities

Ongoing process

- 2 ■ Improving IT infrastructure (HIS & ERP) commensurate to business growth

Ongoing Process

- 3 ■ Rebranding of NMC Health to widen appeal and addressable market



- 4 ■ Operational strategy focused on maximisation of productivity, efficiency and capacity

Ongoing Process

- 5 ■ Financing optimisation to increase funding capabilities while lowering cost of funds



Contents

1. FY 2014 highlights
2. Financial performance & analysis
3. Strategy update
4. **New Financing facility**
5. Acquisition
6. Outlook
7. Appendix

NMC Health secures US\$ 825m facility

- On 16 February 2015 NMC Health secured US\$825m facility from regional and international banks
- Group secured improved terms, lowering cost of debt and prepared for next stage of NMC's growth
- Facility is comprised of two tranches:
 - 1. US\$350m amortizing five years term loan facility**
 - i. Purpose is repayment of existing debt, reduction in financing cost and for general corporate use. Expected savings amount to US\$ 2.75-3.75m annually, based on year end leverage levels
 - ii. Interest Rate: Based upon the current leverage of the NMC group (the 'Group'), the initial margin is expected to be 100bps/70 bps over 1 month LIBOR/EIBOR, although the pricing of the financing may fluctuate according to certain variables agreed in the underwriting documents
 - iii. Currency: US\$ / AED
 - 2. US\$ 475m five year delay draw facility**
 - i. Purpose is acquisitions
 - ii. Availability: At any time during 2 years from the facility agreement signing date with a 1 year extension option
 - iii. Interest rate: Calculated as a margin over 1 month LIBOR / EIBOR which may fluctuate according to certain variables agreed in the underwriting documents
 - iv. Acquisition announced today did not utilise any funds from this facility

Contents

1. FY 2014 highlights
2. Financial performance & analysis
3. Strategy update
4. New Financing facility
- 5. Acquisition**
6. Outlook
7. Appendix

NMC acquires Clinica Eugin, a leading global fertility centre


- On 23 February, NMC Health entered into an agreement to acquire 86.4% of issued share capital of Clinica Eugin (Eugin)
- Based in Barcelona and founded in 1999, Eugin is amongst the largest European providers of fertility treatments, in terms of the number of cycles performed annually, and has the largest egg bank in Europe
- The acquisition of Eugin allows NMC to achieve several key elements of its recently updated Group Strategy and is supported by a strong strategic rationale:
 - Brings leading global expertise and technologies in fertility services to NMC's network in the UAE and strongly complements existing NMC women's health services
 - Accelerates the development of NMC into a centre of clinical excellence for women's health and will allow NMC to establish a foothold in the UAE medical tourism market
 - Significant potential for revenue synergies from growing Eugin's franchise in the UAE and the broader GCC/MENA region
 - Transaction expected to be significantly accretive in Year 1 with positive effect on margins and attractive ROIC
 - Eugin's strong and experienced management team have agreed to remain at the Company, limiting potential integration risk
- Total Enterprise Value of €143m. Transaction did not utilise recently announced facility
- 2014 revenues of €34.3m, EBITDA of €14.0m and EBITDA margins of 41%
- Website: <http://www.eugin.co.uk>

Eugin is amongst Europe's top-three providers of fertility treatments


Overview

- Eugin is amongst the leading European providers of fertility treatments with full range of fertility treatments
- More than 5,000 patients and c. 8,000 cycles in 2014
- Largest egg bank in Europe providing c.10% of donor IVF
- Leader in cross-border fertility treatments in Europe
- Market leading success rates with almost no waiting lists
- Over 95% of Eugin's patients are referred from outside Spain. Main countries of patient origins:
 - France (55%)
 - Italy (17%)
 - Switzerland (4%)
 - MENA (3%)
 - UK (2%)

Revenue contribution by treatment



Patients by nationality




UAE market supply/demand gap in IVF cycles presents opportunity for NMC


Dubai's target medical tourism growth

- Infertility is a growing medical issue within the UAE, according to Frost & Sullivan (F&S)
- Approximately one in six couples experience fertility problems
- Shortage of world class fertility treatment facilities in the country with supply capacity shortfall of 8,500 IVF cycles in 2013, 50% of the estimated 2013 demand
- As of 2014, infertility procedures have also been identified by Dubai Health Care City's (DHCC) recent survey as the leading treatment sought by medical tourists visiting the Emirate.
- Top-five treatments sought by medical tourists to the UAE:
 1. Infertility
 2. Cosmetic
 3. Dental
 4. Cardiac
 5. Orthopaedics
- Dubai Health Authority announced plans to attract 500,000 medical tourists by 2020, generating over \$700m in revenues.


Dubai's medical tourism growth target



UAE 2013 IVF Cycles Demand / Supply Gap Analysis ('000)



Eugin will Reposition NMC on Multiple Fronts



Contents

1. FY 2014 highlights
2. Financial performance & analysis
3. Strategy update
4. New Financing facility
5. Acquisition
6. **Outlook**
7. Appendix

Positive outlook

- UAE macro-economic outlook for 2015 is positive with the anticipated GDP and population growth expected to support our expansion
- We expect accelerated ramp-up in the recently opened facilities, with the opening of inpatient services and growing marketing impact
- Mandatory medical insurance in Dubai is gaining traction and is expected to start having positive effects on healthcare market towards the end of the year
- Contribution from Clinica Eugene will be earnings accretive. We expect to introduce services in the UAE initially and explore complementary opportunities and synergies
- Early stage discussions ongoing on potential additional acquisitions
- We expect 2015 to be another rewarding year for NMC Health and its shareholders

Contents

Q&A

Contents

1. FY 2014 highlights
2. Financial performance & analysis
3. Strategy update
4. New Financing facility
5. Acquisition
6. Outlook
7. **Appendix**

Contents

Appendix

Senior management presenting

Senior management presenting



Mr. Prasanth Manghat
Deputy CEO

Mr Manghat has had a number of roles within NMC related businesses for the last 12 years including, prior to his current role, as Chief Financial Officer of NMC Health for 5 years. As CFO, he was primarily responsible for running the Company's finance function including treasury, corporate finance and accounting.

Mr Manghat spearheaded NMC Healthcare's successful listing on the Premium Segment of the London Stock Exchange (LSE) in April 2012. This was a landmark transaction in many ways, being the first UAE company to list on the LSE and raising US\$187 million in the process. Mr Manghat has played a major role in the growth of the NMC businesses both prior to and since the IPO.

Mr Manghat was honoured with the "CFO of the Year" award – 2012 by ICAEW, Middle-East. He was also conferred with the prestigious award for "Excellence in Finance" by the Institute of Chartered Accountants of India, Abu Dhabi Chapter in Nov, 2012 and "Professional Excellence Award in the Healthcare Sector" by ICAI UAE (Dubai) Chapter in May 2013.

Prior to joining NMC, Mr Manghat has worked as Credit and Operations Head with Kotak Mahindra Finance, one of the leading non-banking financial institutions in India. A Fellow member of the Institute of Chartered Accountants of India (FCA), Bachelor of Science (1995), MG University, Kerala, India, CIA, ACCA from UK (2004) and pursuing CA (Institute of Chartered Accountants of England and Wales), he has 14 years of experience in management of treasury and banking functions, corporate finance, accounting and financial reporting activities.

Mr Manghat assumed the role of Deputy Chief Executive Officer of NMC Health plc with effect from 1 January 2015. In his new role, Mr Manghat's responsibility will extend to cover strategic matters and to support the Chief Executive Officer with planning and strategy execution across both of NMC's Divisions.

Senior management presenting (continued)



Mr. Roy Cherry

Head of Strategy & Investor Relations

Mr Cherry works closely with the Executive Vice Chairman & CEO and Deputy CEO on NMC Health's strategy.

He also leads the Group's investor relations efforts. Mr Cherry played an instrumental role in the re-rating of NMC's shares by investors and analysts, with the company's shares being among the top-10 best performing on the London Stock Exchange in 2013.

His career includes PwC Transaction Services where he advised on feasibilities and M&A transactions with a combined transaction value exceeding US\$10bn across a variety of sectors including healthcare. He previously headed the Equity Research Department at SHUAA Capital in Dubai, one of the region's first and most acclaimed equity research teams. Mr Cherry played an important role on several regional IPOs including, Saudi Catering, NMC Health, Deyaar, DP World and Royal Jordanian Airlines.

Immediately prior to joining NMC Health, Mr Cherry was with Saudi Fransi Capital, where he was the Head of Research & Advisory Department. He holds a BSc in Management from the University of London. In addition to English, he is a fluent speaker of both Arabic and Swedish.

Senior management presenting (continued)



Mr. Suresh Krishnamoorthy

CFO

Mr Krishnamoorthy was appointed Chief Financial Officer of the Company with effect from 1 January 2015.

He joined NMC in December 2000 as an Internal Audit Manager and he continued in this role until March 2011. Since April 2011 Mr Krishnamoorthy has worked as a senior member of NMC's finance team, having significant involvement in the Company's IPO and in the Company's major fund raising initiatives. Prior to be appointed as Deputy Chief Financial Officer in July 2014, he was responsible for the MIS and Corporate Planning portfolio including close involvement in the Group's internal and external audits and other Audit Committee activities since its inception following IPO.

Prior to joining NMC, he worked as Assistant Finance Manager in Kerala Industrial Infrastructure Corporation (KINFRA), a Government agency involved in the development of infrastructure in the State of Kerala.

Mr Krishnamoorthy qualified as a Chartered Accountant from the Institute of Chartered Accountants of India in Nov 1998. He has 16 years of experience in the field of audits, corporate finance, accounting and financial reporting activities.